Search - tctmd.com

Displaying 561 - 580 of 855

Sort: Relevancy | Date

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

News Conference News AHA 2020

INVESTED: No Added CV Benefit From High-Dose Flu Vaccine

November 17, 2020

News Industry News

Corvia Medical Completes Randomization In Reduce Lap-Hf II Pivotal Trial And Gains Fda Authorization To Provide Continued Access For The Corvia Atrial Shunt

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

Clinical Trial Conduct in the COVID-19 Era: A Road Map

News Daily News

Clinical Trial Conduct in the COVID-19 Era: A Road Map

November 12, 2020

CMS Weighs Medicare Coverage at the Time of FDA Approval for Breakthrough Devices

News Daily News

CMS Weighs Medicare Coverage at the Time of FDA Approval for Breakthrough Devices

Michael O'Riordan

October 30, 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

News Conference News TCT 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

Michael O'Riordan

October 17, 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

News Conference News TCT 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

October 16, 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

October 12, 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

October 09, 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

More HF Readmissions Among Black People From Deprived Neighborhoods

News Conference News HFSA 2020

More HF Readmissions Among Black People From Deprived Neighborhoods

October 06, 2020

TCTMD’s Top 10 Most Popular Stories for September 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

October 01, 2020

TAVR Delays During Pandemic’s Peak Led to Hospitalizations, Deaths

News Daily News

TAVR Delays During Pandemic’s Peak Led to Hospitalizations, Deaths

Michael O'Riordan

September 30, 2020

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

September 30, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

As Interventions Dip During COVID-19, CMS Offers Leniency on Volumes

News Daily News

As Interventions Dip During COVID-19, CMS Offers Leniency on Volumes

September 23, 2020

Open Letter Calls on CV Societies to Discourage CMR After Mild COVID-19

News Daily News

Open Letter Calls on CV Societies to Discourage CMR After Mild COVID-19

September 15, 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.